eureKARE wins EU grant to lead SYNBEE project
The European project will enhance the commercial potential of one of today’s most disruptive fields
We invest in synthetic biology innovations
To bring disruptive technologies in health, environment and sustainable manufacturing to market.
Science is in our DNA
Most of our team has advanced training in science and our Science Advisory Board is top-notch; We promote science-based pitch competitions to discover and support ambitious SynBio projects
Highly specialized
100% dedicated to investment in SynBio
Our network
Spans many niche areas of SynBio research and commercialization across Europe. We nurture it through our Annual SynBio Day and other activities
Rare cross-sector investment portfolio
Our investments are at different stages of growth and span health, environment and sustainable manufacturing
We’re investing in the next big revolution
Synthetic biology and applies techniques from engineering and computer sciences to biology. We believe it will revolutionize how we live, eat, and protect our planet
60%
of the materials we use could be made using biological means
Over 400
use cases spanning applications in healthcare, manufacturing, agriculture, energy and the environment
Up to 4Tn US$
the value projection of direct economic impact of innovation in SynBio is estimated to be by 2040
Our investment model
We act as a bridge between academia and industry, financing and developing synthetic biology innovation across Europe, UK, and Israel through an innovative investment model geared towards very early-stage start-ups and more mature SynBio companies
€
25
M
Launched in 2021
1
Companies financed
1
Biotech Start-Up Studios
1
st
SPAC dedicated to bio-manufacturing in Europe
Editions of our International Conference SynBio Day
>
150
Scientific projects evaluated
Our areas of focus
We’re convinced that the right SynBio innovations will provide solutions to major challenges of our time.
Health
We’ve made 9 investments in the health space, including a SPAC. These span biomanufacturing, gene and cell therapies, microbial drugs, DNA synthesis, and more.
Environment
We’ve launched a new biotech studio in Monaco focused on environmental applications. Investments and projects in this space are in the pipeline and currently under evaluation.
Sustainable manufacturing
We’ve made a first investment in Biomemory, a startup working on DNA data storage. All of our investments and start-ups created in climate and sustainability innately align with ESG principles.
News
Stay up to date with our latest news and events
eureKARE co-founds EonBio to revolutionize drug discovery with pioneering cell-free technology on a chip
eureKARE announces EonBio as the second company to be supported by its Belgium biomedical start-up studio
eureKARE appoints Anne Lauvergeon as a new Board member
Ms. Lauvergeon brings an extensive background in the management of large energy corporations (most notably as CEO of Areva), finance, and government.
Let’s build something together!

Whereas you are curious about our projects, investment or biotech studios – we’ve ready to answer any and all quastions.
